Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 10/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 10/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 10/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 10/20 | 0.38 |
| ▸ | LTA4H | P09960 | 4/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2109364 | 0.99 | HTR1A (0.39) | HTR1AADRA1DADRA1AADRA1BLTA4H | |
| SCHEMBL9458455 | 0.76 | TSHR (0.41) | — | |
| SCHEMBL751259 | 0.76 | TSHR (0.41) | — | |
| SCHEMBL11451929 | 0.69 | TSHR (0.37) | — | |
| SCHEMBL11452742 | 0.68 | ADRA1A (0.47) | ADRA1A | |
| SCHEMBL16973469 | 0.64 | TSHR (0.45) | — | |
| SCHEMBL10759760 | 0.64 | TMEM97 (0.49) | HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL25197896 | 0.64 | SIGMAR1 (0.64) | HTR1AADRA1DADRA1AADRA1BLTA4H | |
| Hydrochloric Acid SCHEMBL30904664 | 0.63 | HTR1A (0.67) | HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL16507131 | 0.62 | SLC6A4 (0.55) | HRH1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-4692178-A1 | CELLULOSE POWDER AND MOLDED BODY | Asahi Kasei Kabushiki Kaisha (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-12427113-B2 | Cellulose composition, tablet, and orally disintegrating tablet | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2025-09-30 | — | — | US | disclosed |
| WO-2025105451-A1 | SOLID PREPARATION | 第一三共ヘルスケア株式会社 | 2025-05-22 | — | — | WO | disclosed |
| WO-2025100523-A1 | METHOD FOR PRODUCING SOLID PREPARATION, AND TABLETS | 第一三共ヘルスケア株式会社 | 2025-05-15 | — | — | WO | disclosed |
| WO-2025100462-A1 | SOLID COMPOSITION CONTAINING BROMHEXINE | 第一三共ヘルスケア株式会社 | 2025-05-15 | — | — | WO | disclosed |
| US-12290602-B2 | Cellulose powder, use thereof, and tablets | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2025-05-06 | — | — | US | disclosed |
| EP-4056637-B1 | CELLULOSE COMPOSITION AND TABLET | ASAHI CHEMICAL IND (JP) | 2025-02-12 | — | — | EP | disclosed |
| CN-112585192-B | Cellulose powder, use thereof and tablets | 旭化成株式会社 | 2023-11-21 | — | — | CN | disclosed |
| US-20230055674-A1 | CELLULOSE COMPOSITION AND TABLET | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2023-02-23 | — | — | US | disclosed |
| CN-101203553-A | Porous cellulose aggregate and molding composition thereof | ASAHI CHEMICAL CORP (JP) | 2008-06-18 | — | — | CN | disclosed |
| US-7335776-B2 | Remedies for depression containing EP1 antagonist as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-02-26 | — | — | US | disclosed |
| EP-1873196-A1 | POROUS CELLULOSE AGGREGATE AND MOLDING COMPOSITION THEREOF | Asahi Kasei Chemicals Corporation (JP) | 2008-01-02 | — | — | EP | disclosed |
| US-20070190017-A1 | Porous cellulose aggregate and formed product composition comprising the same | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1712583-A1 | POROUS CELLULOSE AGGREGATE AND FORMED PRODUCT COMPOSITION COMPRISING THE SAME | Asahi Kasei Chemicals Corporation (JP) | 2006-10-18 | — | — | EP | disclosed |
| US-20040082653-A1 | Remedies for depression containing ep1 antagonist as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1369129-A1 | REMEDIES FOR DEPRESSION CONTAINING EP1 ANTAGONIST AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-12-10 | — | — | EP | disclosed |
| EP-0665009-B1 | CRYSTALLINE CONDITION DISLOCATING METHOD | NIPPON SHINYAKU CO LTD (JP) | 2000-02-16 | — | — | EP | disclosed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | disclosed |
| EP-0665009-A1 | CRYSTALLINE CONDITION DISLOCATING METHOD | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1995-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082653-A1 | Remedies for depression containing ep1 antagonist as the active ingredient | PTGER1, PTGER2, PTGS1 | HTR1A 13/4885ADRA1D 169/4885ADRA1A 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.